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Abstract  
Background: To achieve high image quality of cardiovascular magnetic resonance (CMR) 
pulmonary vein (PV) angiography prior catheter ablation in patients with atrial fibrillation, 
optimal timing of the angiographic sequence during contrast agent passage is important. The 
present study identified influential cardiovascular parameters for prediction of contrast agent 
travel time. 
Methods: 106 consecutive patients underwent a CMR examination including 3-dimensional 
contrast-enhanced PV angiography with real-time bolus tracking prior to catheter ablation. 
Correct scan timing was characterized by relative signal enhancement measurements in the 
pulmonary artery, left atrium (LA), and ascending aorta. Furthermore, left- and right-
ventricular function, left- and right-atrial dimensions, presence of mitral or tricuspid 
insufficiencies, and main pulmonary artery diameter were determined. 
Results: The highest relative signal enhancement in LA demonstrated optimal scan timing. 
Contrast agent travel time showed wide variability (range: 12–42 s; mean: 18 ± 4 s). On 
univariate analysis, most cardiovascular parameters correlated with contrast agent travel time 
while on multivariate analysis left- and right-ventricular function remained the only 
independent predictors, but overall a poor fit to the data (adjusted R2, 27.5%) was found. 
Conclusions: Contrast agent travel time was mainly influenced by left- and right-ventricular 
function but prediction models poorly fitted the data. Thus, 3-dimensional PV angiography 
prior to PV ablation procedures necessitates real-time assessment, with visual determination 
of individual contrast agent passage time to ensure consistently high CMR image quality. 
Key words: cardiovascular magnetic resonance imaging, angiography, pulmonary vein, 
atrial fibrillation, catheter ablation 
 
Introduction 
Atrial fibrillation (AF) is a common type of cardiac arrhythmia with a greater prevalence 
in the elderly [1] and in patients with cardiac comorbidities. Prior studies revealed the 
pulmonary veins (PV) as important triggers for initializing and sustaining AF [2]. Treatment 
of AF with catheter ablation aimed at electrical isolation of PVs is nowadays widely 
employed to prevent recurrent AF [3, 4]. 
Prior to PV isolation procedures, 3-dimensional (3D) imaging of the left atrium (LA) and 
PV anatomy is recommended for pre-procedural planning and therapy guidance during 
catheter ablation. These high-resolution images allow for accurate assessment of anatomical 
variants and can be obtained by either multi-detector computed tomography (MDCT) or 
cardiovascular magnetic resonance (CMR) [4, 5]. However, MDCT exposes the patient to 
iodinated contrast agents and ionizing radiation [6] and AF is a chronic, progressive disease 
making repeat examinations during life-time very likely. CMR imaging has the additional 
benefit of combining PV angiography with functional cardiac imaging or myocardial tissue 
characterization (e.g. LA fibrosis) during a single-session examination [7]. Consequently, 
CMR may be considered the preferred imaging approach; the segmented 3D CMR mesh 
models of the LA and the PVs can be easily co-registered in the electroanatomical mapping 
systems and subsequently used for catheter guidance during the ablation procedures, thereby 
significantly reducing overall radiation exposure time [8, 9]. 
High spatial resolution together with high image quality of contrast-enhanced PV 
angiography is mandatory for electrophysiological procedures and hence, the optimal scan 
timing during contrast agent passage plays a pivotal role. Whether the presence of AF during 
CMR imaging affects the contrast agent travel time has not yet been investigated. Moreover, 
predicting the optimal scan timing in an individual patient prior to CMR angiography would 
be highly desirable. Consequently, the present study sought to evaluate various routine 
cardiovascular parameters with regard to their influence on contrast agent bolus travel time 
 
Methods 
Patients 
106 consecutive patients (62 ± 10 years, 61 men) with AF or non-isthmus dependent left-
atrial flutter (AFl) underwent CMR imaging prior to clinically indicated catheter ablation. 
Patients with known contraindications to CMR imaging were not considered. Detailed patient 
characteristics are provided in Table 1. The study was conducted in accordance with the local 
institutional review board and the standards of the University of Leipzig ethics committee. 
Written informed consent was obtained from all patients. 
CMR imaging protocol 
All CMR examinations were performed using a 1.5T MR scanner system (Philips Ingenia, 
Best, The Netherlands) equipped with Omega HP gradients (45 mT/m, 200 T/m/s) and a 28-
element array coil with full in-coil signal digitalization combined with optical transmission. 
Conventional cine imaging was performed in all cardiac standard geometries (short axis 
geometries and long axis geometries, i.e. 4-, 2-, and 3-chamber orientation) using steady-state 
free precession (SSFP) sequences during end-expiratory breath holds with a prospective 
electrocardiogram (ECG)-gating acquisition. In addition, a 3D navigator-gated, balanced 
turbo field echo (bTFE) sequence was acquired in transversal slice orientation with full 
coverage of the great thoracic vessels. Furthermore, phase-contrast flow measurements were 
performed for the assessment of the cardiac output. Finally, contrast-enhanced 3D CMR 
angiography of the LA and PV was performed during inspiratory breath-holding using a non-
ECG triggered spoiled gradient echo sequence (TR/TE/ﬂip angle: 2.2 ms/0.8 ms/30°, 
isotropic spatial resolution: 1.0 × 1.0 × 1.0 mm³). During intravenous bolus injection of 0.1 
mmol/kg Gad-DTPA (Magnograf®, injection rate 4.0 mL/s) followed by a 25 mL saline flush 
at the same injection rate, integrated real-time bolus tracking in coronal slice orientation (slice 
thickness, 150 mm; in-plane spatial resolution, 1.7 × 1.7 mm2; temporal resolution, 680 ms) 
allowed for visual determination of the sequence start as performed by a trained CMR 
operator; the angiographic scan was initiated when the contrast agent bolus arrived in the left 
atrium. 
CMR image analysis 
Cine imaging was used to determine left-ventricular volumes and function, right-
ventricular function and left-/right-atrial size according to standard definitions. Maximal 
diameter of the main pulmonary artery was measured on 3D bTFE scan. 
In order to objectively determine the correct scan timing of PV angiography, signal 
intensity measurements were carried out in the pulmonary artery (PA), the LA, the ascending 
and descending aorta, and in the adipose tissue of the anterior chest wall; relative signal 
enhancement was calculated by dividing the maximum signal intensity of the target region by 
the signal intensity of the reference tissue (= subcutaneous fat). 
Echocardiography 
In all patients, 2-dimensional transthoracic echocardiography was performed within 1 
week prior the CMR examination using a commercially available ultrasound system (Vivid 7, 
General Electric, Milwaukee, WI, USA) equipped with a 3.5 MHz transducer. Recordings 
were made in parasternal long- and short-axis, as well as apical 4- and 2-chamber views. 
Valve morphology and function were assessed according to the guidelines of the European 
Society of Cardiovascular Imaging [10] and the American Society of Echocardiography [11]: 
the severity of mitral and tricuspid regurgitation was graded on a four-point scale. In addition, 
systolic pulmonary artery pressure (PAP) was estimated based on tricuspid regurgitation 
velocity. 
Statistical analysis 
Continuous variables are stated as mean ± standard deviation if normally distributed. 
Numbers and ratios were used to describe categorical variables. The Kolmogorov-Smirnov 
test was used to assess normal distribution. The Chi-square-test was used for comparisons 
between groups in case of categorical variables; the student t-test was applied for continuous 
variables. To determine the relationship of contrast agent travel time and cardiovascular 
parameters, univariate logistic regression analysis was done. Parameters which yielded as 
statistically significant in univariate logistic regression analyses were assessed by multivariate 
logistic regression analysis. In addition, univariate and multivariate regression analysis was 
performed in the subgroups of patients presenting with sinus rhythm or AF during CMR 
examination and estimation models based on polynomial data fitting were derived. A two-
tailed p-value < 0.05 was considered significant. 
Results 
Patient characteristics 
Cardiovascular magnetic resonance examinations were successfully completed in all 106 
patients (Fig. 1). Patient demographics are summarized in Table 1. 
Contrast agent travel time 
The relative signal enhancement of large thoracic vessels and cardiac cavities served as a 
quality measure of accurate timing of the 3D angiographic scan with the highest relative 
signal enhancement observed in the LA (LA 5.1 ± 1.5; PA 2.1 ± 1.1; ascending aorta 4.3 ± 
1.2; descending aorta 4.0 ± 1.3; p < 0.001; Fig.2); in 100% (106/106) and 98% (104/106) of 
patients relative signal enhancement was found to be higher in the LA when compared to the 
main PA and the ascending aorta, respectively. The travel time of the contrast agent bolus was 
normally distributed (Kolmogorov-Smirnov test, p = 0.11) and demonstrated a wide 
variability (range 12–42 s; mean 18 ± 4 s; median 17 s; Figs. 3, 4). 
In order to simulate angiographic scan timing done without real-time display of contrast 
agent bolus passage, derived mean and median values with an allowed deviation of ±1 s were 
employed as “fixed” timing parameters for the current study population: theoretically, such an 
approach would have yielded successful timing in only 16% and 20% of patients within the 
predefined ranges of 17–19 s and 16–18 s, respectively. 
To determine the influence of various routine cardiovascular parameters on the contrast 
agent travel time, univariate analysis was performed and revealed a significant correlation of 
the contrast agent travel time with age, heart rhythm, left and right ventricular ejection 
fraction (LVEF, RVEF), left ventricular end-diastolic volume, left and right atrial size, PA 
diameter, presence of mitral or tricuspid regurgitation and systolic pulmonary arterial 
pressure, respectively (Table 2). On multivariate analysis, left and right ventricular ejection 
fraction remained the only independent predictors of the contrast agent travel time (p = 0.002 
and p < 0.001, respectively); however, the adjusted R2 of 27.5% indicated that the regression 
model poorly fitted the data. 
In addition, subgroup analysis in patients presenting with sinus rhythm or AF during the 
CMR examination was carried out (Table 2) using linear regression analysis: LVEF and 
RVEF remained the only independent predictors of contrast agent travel time in sinus rhythm 
patients while in AF patients none of the cardiovascular parameters reached the level of 
significance (adjusted R2-values, 54% and 12%, respectively). 
In order to derive estimation models for the prediction of contrast agent travel time in 
patients with sinus rhythm, LVEF and RVEF were employed in polynomial curve fitting 
procedures. Based on R2 change, quadratic models were identified to represent a favorable 
compromise between model complexity and routine applicability (Table 3). Though 
significant, explaining only an additional 2% or 9% of the variance was considered not to 
justify rendering the model even more complex and hence, the cubic fit was rejected. 
Respective estimation models for the calculation of predicted contrast agent travel time are 
provided in Table 4. 
 
Discussion 
The present study evaluated the influence of various cardiovascular parameters on the 
contrast agent travel time as assessed during contrast-enhanced CMR pulmonary vein 
angiography prior to catheter ablation of AF. The main findings were as follows: (1) on 
univariate analysis numerous cardiovascular parameters had an influence on contrast agent 
travel time, however (2) on multivariate analysis the only independent predictors were 
identified as LVEF and RVEF; (3) a reliable prediction of the contrast agent travel time was 
not accurately possible for every individual patient in particular in patients with AF during 
CMR examination; (4) in the subgroup of patients presenting with sinus rhythm contrast agent 
travel time may be determined from LVEF and RVEF using the proposed polynomial 
estimation model; (5) finally, visual determination of contrast agent bolus arrival in the target 
region (i.e. the left atrium) using a real-time tracking sequence enabled accurate timing of 
image data acquisition in all patients. 
Three-dimensional angiographic determination of PV and left atrial anatomy can assist in 
pre-procedural decision making (e.g. cryoablation vs radiofrequency ablation technique) and 
is particularly important for anatomical guidance during the ablation procedure [4]. 
Depending on operator preferences, image fusion of pre-procedural CT/CMR anatomic 3D 
reconstructions with electro-anatomical maps can contribute in facilitating complex AF 
ablation procedures [12]. In addition, high-resolution, 3D depiction of the LA and PV 
morphology resulting from image fusion reportedly increased safety of the AF ablation 
procedures [13] and is fundamental in the prevention of rare, but severe procedure-related 
complications such as PV stenosis [14]. 
For high-quality, contrast-enhanced 3D CMR angiography accurate timing of bolus 
arrival in the LA/PV target region is of the essence. Although real-time tracking which 
permits the direct visualization of the bolus passage has been established for several years, 
data from a multicenter trial revealed a high proportion of technical failures due to timing 
errors of up to 25% for CMR angiography of the pulmonary arteries with a proportion of 
technically inadequate images ranging from 11% to 52% between different centers [15]. 
Obviously, a reliable prediction of the correct timing to assist the CMR operator would be 
highly desirable. In the current study population, the distribution of the contrast agent travel 
time showed a high variability which on theoretical simulation using a fixed timing value 
(mean or median) would have resulted in 84% or 80% of inaccurately timed angiographic 
scans, respectively, and thus, leading to inadequate contrast enhancement and impaired image 
quality in a majority of patients. 
Consequently, the current study examined a variety of readily available cardiovascular 
parameters and tested their influence on the contrast agent travel time with the aim to better 
predict scan timing. While on univariate analysis several cardiovascular parameters were 
associated significantly with contrast agent travel time, left and right ventricular function 
remained the only independent predictors on multivariate analysis. However, the low adjusted 
R2 indicated that the regression model poorly fitted the data. A subgroup analysis of patients 
presenting with AF during CMR examination demonstrated that prediction of scan timing will 
almost invariably fail. On the other hand, the subgroup of sinus rhythm patients yielded a 
considerably higher adjusted R2 value suggesting that a prediction of the contrast agent travel 
time may be possible. An estimation model, using a linear fit provided an easily applicable 
approach in clinical routine by calculating 35 or 31 minus one-third of LVEF or RVEF, 
respectively. An improved, though more complex estimate could be achieved by applying a 
quadratic model given in Table 4. However, the adjusted R2 values indicated that only 54% of 
the overall variation could be explained by the independent variables LVEF and RVEF. Thus, 
it must be noted that the possibilities to predict the contrast agent travel time in an individual 
patient are severely limited. 
To overcome these timing challenges, alternative imaging approaches have been 
introduced. Free-breathing ECG-gated 3D SSFP sequences render the correct timing process 
needless: in a small patient study [16] a non-contrast enhanced imaging approach proved to be 
highly accurate with regard to PV diameter measurements when compared to contrast-
enhanced CMR angiography. Another study [17] applied an accelerated free-breathing, ECG-
triggered contrast-enhanced pulmonary vein CMR angiographic scan with isotropic spatial 
resolution using compressed sensing, resulting in even further improvement of vessel 
sharpness when compared to conventional CMR angiography. However, the fundamental 
prerequisite for all these ECG-triggered imaging approaches consists in the presence of a 
regular sinus rhythm. But considering the patient population scheduled for PV angiography 
prior to electrophysiological ablation procedures, a high proportion of patients will present 
with AF and, thus, a high heart rate variability. In the present study, nearly half of the patients 
had AF during the CMR examination (48%) and consequently, a non-ECG triggered imaging 
approach such as the conventional contrast-enhanced PV angiography is generally preferred. 
A widely used alternative to real-time tracking of the contrast agent bolus is the 
administration of a small test bolus in order to estimate the arrival time in the target region. 
General disadvantages of test bolus timing include increased examination duration and 
background contamination by gadolinium (potentially leading to unfavorable pulmonary 
tissue enhancement and decreased PV conspicuity). More importantly, the arrival times for a 
small contrast agent dose and the full dose are not necessarily consistent. Finally, taking into 
account high heart rate variability of AF patients with concomitant rapid changes of 
hemodynamics, it is evident that the test bolus strategy can be regarded inherently flawed in 
this particular patient population. 
Finally, another important CMR imaging approach has become available with the advent 
of time-resolved 3D-CMR angiographic scans (so called “4D-CMR angiography” with time 
representing the fourth dimension). This scan technique allows  the acquisition of full 3D-
angiographic datasets of the thorax/large thoracic vessels in a time-resolved manner (i.e. 
usually every 4 to 6 s) but this is at the expense of spatial resolution. The technique mostly 
obviates the need for accurate bolus timing since during post-processing a CMR expert selects 
a single, high signal enhancement 3D-dataset of the left atrium/the pulmonary veins for 
diagnostic evaluation and volume rendering/mesh reconstruction. However, the lower spatial 
resolution of 4D-angiographic scans (non-isotropic datasets, typically 2.5 × 2.5 mm2 in-plane 
resolution with 5 mm slice thickness) in comparison to bolus-tracking directed 3D-
angiographic scans (preserved high isotropic spatial resolution, usually in the range of 1.0 × 
1.0 mm2 in-plane resolution with 1.0 mm slice thickness) should be taken into account when 
establishing a routine institutional angiographic protocol: with 4D-CMR angiography small 
caliper PV anatomical variants (early small caliper branching of PV main ostia or accessory 
PVs e.g. right middle PVs, isolated roof top veins etc.) may be poorly visible or even missed 
and, if electrically active, may represent a possible focus for re-occurrence of AF. Hence, at 
the documented institution, the interventional electrophysiologists generally prefer bolus-
tracking directed, high spatial resolution 3D-angiography for anatomical procedural guidance. 
 
Conclusions 
For the determination of contrast agent travel time, left and right ventricular function were 
identified as the only independent predictors but regression models poorly fitted the data, 
particularly in patients with AF during CMR examination. Thus, 3D, PV angiography prior to 
PV ablation procedures necessitates a real-time assessment with visual determination of 
individual contrast agent passage time to ensure consistently high CMR image quality. 
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Figure 1. A. Maximum-intensity projection of 3-dimensional (3D) contrast-enhanced 
cardiovascular magnetic resonance (CMR) angiography of left atrium and pulmonary veins; 
accurate timing led to the highest relative signal enhancement in left atrium/pulmonary veins; 
B. Segmented volume rendering reconstruction of left atrium and pulmonary veins; 
subsequently generated 3D CMR mesh model can be easily integrated into electroanatomical 
mapping systems for guidance of catheter ablation procedures; C. Image fusion of 
electroanatomical map (EnSite Precision, St Jude Medical, St Paul, MN, US) and CMR mesh 
model of left atrium and pulmonary veins during electrophysiological ablation procedure. 
 
Figure 2. Measurements of relative signal enhancement (mean ± standard deviation) 
confirmed the highest values in left atrium (5.1 ± 1.5; p < 0.001) in comparison to the 
pulmonary artery (2.1 ± 1.1), ascending (4.3 ± 1.2) and descending aorta (4.0 ± 1.3), 
respectively. 
 
Figure 3. Histogram plot of contrast agent travel time in all patients demonstrated a wide 
variability (range, 12–42 s; mean, 18 ± 4 s); the black line indicates fitted normal distribution. 
Figure 4. Real-time cardiovascular magnetic resonance (CMR) bolus tracking during contrast 
agent passage: representative extracted frames of contrast agent bolus passage are shown 
demonstrating its arrival in superior vena cava (SVC), right atrium (RA), right ventricle 
(RV)/pulmonary artery (PA), lung and left atrium (LA); subsequently, 3-dimensional 
angiographic imaging sequence was started; A. Sinus rhythm (heart rate 78/min), LV-EF 
64%, RV-EF 61%, LA 18 cm2, RA 17 cm2, MI grade 1; B. Atrial fibrillation (heart rate 
approx. 100/min), LV-EF 23%, RV-EF 24%, LA 29 cm2, RA 27 cm2, MI grade 1; LY — left 
ventricle; EF — ejection fraction. 
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Table 1. Patient characteristics (n = 106).  
  
Age [years] 62 ± 10 
Women 45 (43%) 
Sinus rhythm during CMR-study 
Heart rate during CMR-study [1/min] 
55 (52%) 
78 ± 26 
Pulmonary disease 6 (6%) 
Body mass index [kg/m2] 29 ± 5 
Left ventricular ejection fraction [%] 
Left ventricular end-diastolic volume [mL] 
Cardiac output [l/min] 
Right ventricular ejection fraction [%] 
53 ± 11 
157 ± 54 
5.9 ± 1.6 
42 ± 8 
Left atrial area [cm2] 29 ± 8 
Right atrial area [cm2] 24 ± 6 
Pulmonary artery diameter [mm] 26 ± 4 
Systolic pulmonary artery pressure [mmHg] 27 ± 8 
Mitral regurgitation ≥ grade 2 10 (9%) 
Tricuspid regurgitation ≥ grade 2 8 (8%) 
Data are provided as mean ± standard deviation or number (percent). CMR — cardiovascular magnetic 
resonance 
Table 2. Univariate and multiple linear regression (MLR) analysis (p-values) for prediction of contrast agent travel time. 
 
 All patients  SR during CMR study  AF during CMR study 
 Univariate MLR   Univariate MLR   Univariate MLR  
Age 0.02 0.14  0.07    0.79   
Sex 0.06   0.1   0.22  
SR during CMR-study 0.01 0.95       
Heart rate during CMR-study 0.12   0.63   0.92  
Body mass index 0.36   0.49   0.87  
LVEF < 0.001 0.01  < 0.001 0.001  0.03 0.16 
LVEDV 0.004 0.17  < 0.001 0.51  0.20  
Cardiac output 0.23   0.21   0.46  
RVEF < 0.001 < 0.001  < 0.001 0.002  0.013 0.057 
LA 0.001 0.65  0.046 0.34  0.052  
RA  0.001 0.61  0.003 0.30  0.15  
Pulmonary artery diameter 0.02 0.24  0.069   0.28  
Systolic PAP 0.025 0.73  0.035 0.56  0.57  
Mitral regurgitation ≥ grade 2 0.001 0.27  0.008 0.52  0.17  
Tricuspid regurgitation ≥ grade 2 0.01 0.58   0.03 0.85   0.39   
         
SR — sinus rhythm; AF — atrial fibrillation; LVEF — left ventricular ejection fraction; LVEDV — left ventricular end-diastolic volume; RVEF — right 
ventricular ejection fraction; LA — left atrial dimension; RA — right atrial dimension; PAP — pulmonary arterial pressure 
Table 3. Polynomial regression analysis to determine the influence of left and right ventricular ejection fraction 
(LVEF, RVEF) on contrast agent travel time in patients with sinus rhythm (n = 55). 
        
 
LVEF 
 
RVEF 
 
R2 Adjusted R2 R2 change 
 
R2 Adjusted R2 R2 change 
Linear model 0.43 0.42 0.43 
 
0.33 0.32 0.33 
Quadratic model 0.56 0.54 0.13 
 
0.55 0.54 0.22 
Cubic model 0.58 0.55 0.02 
 
0.64 0.63 0.09 
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Table 4. Estimation models for calculation of contrast agent travel time (given in seconds) in 
patients with sinus rhythm. 
 
LVEF-based models 
Linear 𝐶𝑜𝑛𝑡𝑟𝑎𝑠𝑡 𝑎𝑔𝑒𝑛𝑡 𝑡𝑟𝑎𝑣𝑒𝑙 𝑡𝑖𝑚𝑒 [𝑠] = 35 − 0.33 × 𝐿𝑉𝐸𝐹 
Quadratic 
𝐶𝑜𝑛𝑡𝑟𝑎𝑠𝑡 𝑎𝑔𝑒𝑛𝑡 𝑡𝑟𝑎𝑣𝑒𝑙 𝑡𝑖𝑚𝑒 [𝑠]
= 58 − 1.4 × 𝐿𝑉𝐸𝐹 + 0.01 × 𝐿𝑉𝐸𝐹2 
RVEF-based models 
Linear Contrast agent travel time [s] = 31 − 0.33 × RVEF 
Quadratic Contrast agent travel time [s] = 61 − 1.8 × RVEF + 0.02 × RVEF2 
 
LVEF — left ventricular ejection fraction (in %); RVEF — right ventricular ejection fraction 
(in %)  
 
 
